Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Enozertinib (ORIC-114) program update presented at ESMO Congress 2026 on October 23, 2026.
Oric Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Enozertinib (ORIC-114) program update presented at ESMO Congress 2026 on October 23, 2026
- Exhibit 99.1 contains the disclosed clinical data, relevant to assessing enozertinib’s development progress
Item 8.01 · Other Events
- Phase 1b efficacy: 84% investigator ORR and 80% BICR ORR across 25 response-evaluable patients
- Intracranial activity: 67% BICR RANO-BM ORR and 40% complete response rate across 15 patients
- CNS relevance: 46% of patients had previously untreated brain metastases, supporting differentiation in a high-need population
- Safety profile: no Grade 4 or 5 treatment-related adverse events and no treatment discontinuations from adverse events
- Redwood-1 global Phase 3 planned for 1H 2027, targeting approximately 360 patients with dual ORR and PFS endpoints
Item EX-99.1 · Exhibit EX-99.1
- Phase 1b data support rapid advancement toward Phase 3 in first-line EGFR atypical NSCLC
- Systemic confirmed ORR 84%, BICR ORR 80%, and 6-month PFS 88% in 25 evaluable patients
- CNS confirmed ORR 70% investigator-assessed and 67% by BICR RANO-BM, including complete responses
- Baseline CNS metastases in 65% of 26 patients, including 46% with previously untreated brain metastases
- Redwood-1 global Phase 3 trial planned for 1H 2027, targeting a US opportunity exceeding $2.5 billion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oric Pharmaceuticals, Inc. 8-K filings
Get the next ORIC 8-K as it lands
Follow ORIC for push alerts, or ask the research agent what this filing means.